HY 075
Alternative Names: HY-075; HY-CVS-075Latest Information Update: 04 Mar 2025
Price :
$50 *
At a glance
- Originator Hyloris Pharmaceuticals
- Class Anticoagulants; Vascular disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Coronary disorders
Highest Development Phases
- Preclinical Coronary disorders
Most Recent Events
- 04 Mar 2025 Preclinical trials in Coronary disorders is underway in Belgium (PO, Liquid) (Hyloris Pharmaceuticals pipeline, March 2025)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Coronary-disorders in Belgium (PO, Liquid)
- 04 Jun 2020 HY 075 is available for licensing as of 04 Jun 2020. https://hyloris.com/